News& Press Releases

Excited to share our contribution to the development of a groundbreaking PET ligand for imaging of non-AD tauopathies! 

We are proud to have the opportunity to work in collaboration together with BioArctic in this study we have been performing IHC binding of Lecanemab in Down syndrome and Alzheimer's disease This study shows for or the first time, Lecanemab (an antibody with higher avidity for toxic Aβ aggregates), binding to Aβ protofibrils and plaques in people with Down syndrome is demonstrated Lecanemab currently in phase 3 clinical studies and has shown to reduce brain amyloid levels in t

New publication, “Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein” together with Karolinska Institutet, Andrea Varrone research group. The approach used in this study also shows that TMAs are a useful tool for the evaluation of ligands in tissue from different proteinopathies, using both fluorescence and autoradiographic assays https://doi.org/10.1016/j.brainres.2020.147131 The neuropathological hallmark o

Offspring Biosciences is pleased to announce our expanded technical capacity with the purchase and installment of a Roche/Ventana Discovery Ultra tissue staining platform which significantly enhances our ability to deliver highly reliable, informative and 7-Plex Multiplex IHC & ISH Services | Preclinical CRO | Offspring Bioefficient support to our customers The Discovery Ultra platform allows for parallel and fully individualized processing of up to 30 slide-mounted tissue

In a recently published study in Plos One, a research team led by Dr Sara Hansson at AstraZeneca presented data which demonstrate that secretagogin, an intracellular calcium-binding intracellular protein highly enriched in pancreatic islets, may serve as biomarker in the blood for beta cell dysfunction in individuals with type 2 diabetes Offspring supported this project by performing multiplexed immunofluorescence-based detection of secretagogin selectively within the insulin

In a recently published study by a research team from MedImmune led by Dr. Arun Sharma, novel data was presented which shows that in vivo treatment with a combination of the neurotrophic factor neuturin (NRTN) and liraglutide in hyperglycemic ZDF rats synergistically improved glycemic control and enhanced metabolic parameters as compared to liraglutide alone, highlighting the potential of novel combinatorial approaches to prevent or reverse diabetes progression Offspring are